Alleviation by leucovorin of the dose-limiting toxicity of edatrexate: potential for improved therapeutic efficacy

[1]  W. Hong,et al.  Phase II study of 10-ethyl-10-deaza-aminopterin (10-EdAM; CGP 30 694) for stage IIIB or IV non-small cell lung cancer , 1990, Investigational New Drugs.

[2]  F. Sirotnak,et al.  New folate analogs of the 10-deaza-aminopterin series , 2004, Cancer Chemotherapy and Pharmacology.

[3]  F. Sirotnak,et al.  New folate analogs of the 10-deaza-aminopterin series Basis for structural design and biochemical and pharmacologic properties , 2004, Cancer Chemotherapy and Pharmacology.

[4]  M. Kris,et al.  Phase I trial and clinical pharmacological evaluation of 10-ethyl-10-deazaaminopterin in adult patients with advanced cancer. , 1988, Cancer research.

[5]  M. Kris,et al.  Phase II study of 10-ethyl-10-deaza-aminopterin in patients with stage III and IV non-small-cell lung cancer. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  R. Schilsky,et al.  High-dose methotrexate: a critical reappraisal. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  F. Sirotnak,et al.  Combination chemotherapy with a new folate analog: activity of 10-ethyl-10-deaza-aminopterin compared to methotrexate with 5-fluorouracil and alkylating agents against advanced metastatic disease in murine tumor models. , 1987, Cancer treatment reports.

[8]  L. Matherly,et al.  The effects on 4-aminoantifolates on 5-formyltetrahydrofolate metabolism in L1210 cells. A biochemical basis of the selectivity of leucovorin rescue. , 1987, The Journal of biological chemistry.

[9]  F. Sirotnak,et al.  10-Ethyl-10-deaza-aminopterin: structural design and biochemical, pharmacologic, and antitumor properties. , 1987, NCI monographs : a publication of the National Cancer Institute.

[10]  C. Mountain,et al.  A new international staging system for lung cancer. , 1987, Chest.

[11]  L. Matherly,et al.  Antifolate polyglutamylation and competitive drug displacement at dihydrofolate reductase as important elements in leucovorin rescue in L1210 cells. , 1986, Cancer research.

[12]  F. Sirotnak,et al.  New folate analogs of the 10-deaza-aminopterin series: markedly increased antitumor activity of the 10-ethyl analog compared to the parent compound and methotrexate against some human tumor xenografts in nude mice. , 1985, Cancer treatment reports.

[13]  L. Mangoni,et al.  High-Dose Methotrexate-Leucovorin Rescue Therapy: Selected Application in Non-Hodgkin's Lymphoma , 1985, Tumori.

[14]  I. Goldman,et al.  Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro. , 1984, Cancer research.

[15]  F. Sirotnak,et al.  Similar specificity of membrane transport for folate analogues and their metabolites by murine and human tumor cells: a clinically directed laboratory study. , 1984, Cancer research.

[16]  L. Frankel,et al.  High-dose methotrexate as part of remission maintenance therapy for childhood acute lymphocytic leukemia: a Pediatric Oncology Group pilot study. , 1983, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. W. Fry,et al.  Role of methotrexate polyglutamylation and cellular energy metabolism in inhibition of methotrexate binding to dihydrofolate reductase by 5-formyltetrahydrofolate in Ehrlich ascites tumor cells in vitro. , 1983, Cancer research.

[18]  W. Evans,et al.  Methotrexate cerebrospinal fluid and serum concentrations after intermediate‐dose methotrexate infusion , 1983, Clinical pharmacology and therapeutics.

[19]  D. W. Fry,et al.  Analysis of the role of membrane transport and polyglutamation of methotrexate in gut and the Ehrlich tumor in vivo as factors in drug sensitivity and selectivity. , 1983, Cancer research.

[20]  F. Sirotnak,et al.  Synthesis and antitumor activity of 10-alkyl-10-deazaminopterins. A convenient synthesis of 10-deazaminopterin. , 1982, Journal of medicinal chemistry.

[21]  A. Miller,et al.  Reporting results of cancer treatment , 1981, Cancer.

[22]  R. Bast,et al.  High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. , 1980, The American journal of medicine.

[23]  H. Kaplan,et al.  A clinical and pharmacological study of high-dose methotrexate with minimal leucovorin rescue. , 1979, Cancer research.

[24]  Jacobsen Sa,et al.  Phase I trial of high-dose methotrexate with modified citrovorum factor rescue. , 1978 .

[25]  S. Jacobs,et al.  Phase I trial of high-dose methotrexate with modified citrovorum factor rescue. , 1978, Cancer treatment reports.

[26]  J. Bertino.  "Rescue" techniques in cancer chemotherapy: use of leucovorin and other rescue agents after methotrexate treatment. , 1977, Seminars in oncology.

[27]  N. Mantel,et al.  Eradication Of Leukaemic Cells (L1210) by Methotrexate and Methotrexate Plus Citrovorum Factor , 1966, Nature.